CXCL2, which regulates breast cancer metastasis and chemo-resistance [43], is also reduced by CDDO-Me treatment (Fig 4D), implicating a potential role for CDDO-Me in the treatment of metastatic disease. Here, CXCL2 is linked to metastatic neoplasm.